Botox Risks and Side Effects: What the Clinical Evidence Actually Shows
Concern about side effects is the most common reason people delay or decline botox treatment. This article does not minimise that concern — it addresses it with the evidence: what adverse effects occur, at what frequency, how long they last, who should not have this treatment, and what the role of practitioner training is in reducing risk.
Botulinum toxin type A has one of the most extensively documented safety profiles in aesthetic medicine — not because it is risk-free, but because it has been used clinically for over 30 years and studied at scale. The question is not whether risks exist. They do. The question is what they are, how often they occur, how long they last, and which of them are preventable.
This article covers the complete risk picture using data from the clinical literature and regulatory positions of FDA, EMA, and INFARMED. For a broader introduction to the treatment, see our complete botox guide for first-timers.
Regulatory status: what approval actually means
Botulinum toxin type A for aesthetic use has been approved by the FDA since 2002, by EMA for EU member states, and is licensed by INFARMED for aesthetic indications in Portugal. Products available in Portugal that meet regulatory requirements include Botox® (Allergan/AbbVie), Azzalure® (Galderma), Bocouture® (Merz), and Nuceiva® (Evolus).
Regulatory approval means that the product's benefit-to-risk profile has been assessed by independent scientific committees using clinical trial data. It does not mean the product is without risk — no approved medical product is. It means the evidence supports that, when used correctly in appropriate patients, the expected benefit outweighs the documented risks.
In Portugal, administration of botulinum toxin is a medical act. Only licensed doctors have the legal authority and the training to perform it. This distinction matters in practice: the majority of documented adverse effects in the published literature involve practitioners without adequate medical training or products outside the regulatory supply chain.
Common temporary effects: frequency and duration
The following effects are documented in the prescribing literature and published clinical studies. They are localised, temporary, and resolve without treatment in the vast majority of cases.
| Effect | Approximate frequency | Typical duration |
|---|---|---|
| Bruising at injection site | 10–25% of patients | 5–10 days |
| Localised swelling (oedema) | 5–15% of patients | 24–48 hours |
| Headache | 5–10% of patients | 24–48 hours |
| Discomfort at injection points | 5–10% of patients | 1–3 days |
| Transient redness (erythema) | 5–8% of patients | Hours |
Bruising is the most common adverse effect and the least preventable — it depends partly on individual vascular anatomy. Risk is reduced by using fine-gauge needles, avoiding aspirin and NSAIDs for 7 days before treatment (where medically appropriate), and applying pressure immediately after injection. Cold compresses in the 24 hours following treatment support resolution.
Headache following forehead treatment is well documented but rarely severe. It is thought to result from local muscle tension changes post-injection and resolves spontaneously within 24–48 hours in most patients. Paracetamol is appropriate; NSAIDs are generally avoided in the immediate post-injection period.
All of the common effects listed above are temporary, self-limiting, and localised. None requires intervention beyond observation and, in some cases, cold compresses. None of them involves systemic toxicity at doses used for facial aesthetics.
Rare complications: what they are and how they occur
The following effects are less common and typically linked to technical factors — injection point selection, dose, or failure to account for individual anatomy. They are temporary but may persist for several weeks.
Eyelid ptosis (drooping)
Ptosis — partial drooping of the upper eyelid — is reported in 1–5% of forehead and glabella treatments in the clinical literature. It results from diffusion of toxin into the levator palpebrae superioris, the muscle that elevates the eyelid. This occurs when injection points are placed too close to the orbital rim, or when the patient applies pressure to the injection site immediately after treatment (which accelerates diffusion).
Duration is typically 2–6 weeks, resolving as the neuromuscular block diminishes. Apraclonidine 0.5% eye drops (available on prescription) can partially compensate for ptosis by activating Müller's muscle, an alternative elevator of the upper lid. This is symptomatic management — it does not accelerate resolution.
Asymmetry
Post-treatment asymmetry may result from anatomical asymmetry that was not assessed before treatment (most faces have pre-existing asymmetry that a careful consultation should document), from differences in product diffusion between sides, or from unequal dosing. In some cases, asymmetry can be partially corrected at the 14-day review by injecting additional product into the undertreated side. Asymmetry resolves fully as the product effect diminishes.
Spock brow
An exaggerated arch of the outer eyebrow — colloquially called "Spock brow" or "devil's eyebrow" — results from blocking the central portion of the frontalis without adequately addressing the lateral portion. The lateral fibres continue to contract, lifting the outer brow disproportionately. It is correctable at the 14-day review with a small dose of toxin to the lateral frontalis.
Dysphagia and neck weakness
Difficulty swallowing (dysphagia) or neck weakness are documented in neck treatments — specifically platysma bands and hyperhidrosis of the neck — where larger volumes are used in proximity to swallowing musculature. These effects are not associated with facial aesthetic doses in the glabella, forehead, and periorbital areas when administered by a trained doctor following standard dosing protocols.
Contraindications: who should not have this treatment
Contraindications are conditions under which treatment is not appropriate. Some are absolute — the treatment must not proceed. Others are relative — they require individual assessment and clinical judgment before a decision is made.
Absolute contraindications
- Pregnancy and breastfeeding. No clinical data on foetal or infant safety. Treatment is contraindicated during both periods.
- Known hypersensitivity to botulinum toxin or excipients. Prior allergic reaction to any botulinum toxin product or its components (typically human albumin used as stabiliser) is an absolute contraindication.
- Active infection at the planned injection site. Injection through infected tissue carries risk of spreading infection and is not appropriate.
- Neuromuscular diseases. Myasthenia gravis, Lambert-Eaton myasthenic syndrome, and amyotrophic lateral sclerosis (ALS) are all conditions that affect neuromuscular transmission. Adding a neuromuscular blocking agent carries clinically unacceptable risk in these patients.
Relative contraindications
The following are not automatic exclusions but require disclosure and individual assessment at consultation:
- Anticoagulant medication (warfarin, new oral anticoagulants, low-dose aspirin for cardiovascular prophylaxis) — increases bruising risk; decision made with prescribing physician where relevant.
- Aminoglycoside antibiotics (gentamicin, tobramycin) — may potentiate the neuromuscular block of botulinum toxin.
- Certain neurological conditions — assessed individually in consultation with the treating neurologist.
- Previous facial surgery — altered anatomy requires experienced assessment before injection planning.
What to disclose at your consultation
Disclose all current medications (including supplements and over-the-counter drugs), any diagnosed neurological or autoimmune conditions, all previous aesthetic treatments in the face (including filler), and any known allergies. This information is clinically necessary, not administrative. A consultation where this history is not taken is not a safe consultation.
Permanent damage: what the evidence shows
At doses used for facial aesthetic indications, permanent adverse effects are not documented in the clinical literature. The neuromuscular block produced by botulinum toxin type A is mechanistically reversible: nerve terminal sprouting occurs over 3–5 months, restoring acetylcholine release at the neuromuscular junction. No evidence of toxin accumulation, systemic neurotoxicity, or permanent muscle atrophy exists at the dose ranges used for facial aesthetics — typically 20–64 units per session for standard facial areas.
The ceiling of the safety data refers specifically to approved products administered by trained medical practitioners. Products outside the regulated supply chain — counterfeit or unregistered botulinum toxin products — have been associated with serious adverse events including systemic botulism. This is not a risk of the treatment; it is a risk of not verifying the legitimacy of the clinic and the product used.
Practitioner training and risk
The largest variable in the adverse event profile of botulinum toxin is practitioner training. The complications listed above — ptosis, asymmetry, Spock brow — are not random. They have identifiable technical causes, most of which relate to inadequate anatomical knowledge, incorrect injection point selection, or failure to calibrate dose to individual muscle strength.
A doctor with specialised training in facial anatomy will:
- Conduct a dynamic facial assessment — evaluating muscle strength and movement patterns — before deciding on injection points and dose.
- Document pre-existing asymmetry and discuss it with the patient before treatment.
- Use dose calibration based on individual anatomy rather than standard protocols.
- Include a 14-day review appointment to assess the result and correct any residual asymmetry.
- Know the anatomical danger zones for each treatment area and the technical measures that reduce diffusion risk (needle gauge, injection depth, post-injection pressure).
In Portugal, verify that any clinic is registered with the ERS health regulator at ers.pt. Ask the treating doctor directly about their specific training in facial aesthetic medicine — not their general medical degree.
Free initial consultation
Facial assessment, medical history review, discussion of concerns — no commitment to treatment.
Questions to ask at your consultation
- Which product is being used, and is it INFARMED-registered and within the regulatory supply chain?
- What is the planned dose for each area, and why?
- What specific training do you have in facial aesthetic medicine?
- Is a 14-day review included, and what is the protocol if there is asymmetry or an unexpected effect?
- What are the contraindications for my medical history and current medications?
A doctor who answers these questions precisely demonstrates adequate training and respect for informed consent. Uncertainty or avoidance of these questions is a meaningful warning sign.
Conclusion
Botox has a well-characterised risk profile built on 30 years of clinical use. The common effects — bruising, swelling, headache — are temporary and localised. The rare complications — ptosis, asymmetry, Spock brow — are mostly preventable with correct injection technique and proper anatomy training. Permanent adverse effects at aesthetic doses are not documented. Contraindications are real and must be assessed individually at consultation.
Risk in practice is substantially determined by who administers the treatment and under what clinical standards. At Cosmo Clinic, the initial consultation is free and includes complete medical history review, dynamic facial assessment, and full discussion of contraindications and expected effects. Learn more about botox treatments at our Lisbon clinic. For a deeper look at common fears around botox — frozen face, addiction, long-term safety — see our botox myths and facts guide.